Clinical Trials Logo

Essential Tremor clinical trials

View clinical trials related to Essential Tremor.

Filter by:

NCT ID: NCT03884231 Not yet recruiting - Parkinson Disease Clinical Trials

MRI Study of Infinity DBS System

Start date: May 1, 2019
Study type: Observational

This is a study of subjects with the St. Jude Medical Infinity deep brain stimulation (DBS) system who undergo an MRI imaging procedure. Enrollment may occur before DBS implant, or when an MRI scan is planned in a subject with an existing implant. There will be a follow-up visit one month after the MRI procedure to document any adverse events and verify device functionality.

NCT ID: NCT03875404 Not yet recruiting - Essential Tremor Clinical Trials

Next-Generation Pre-Operative Targeting for Thalamic DBS in the Treatment of Tremor

Start date: April 2019
Phase: N/A
Study type: Interventional

Researchers are investigating improved methods of targeting deep brain stimulators for treatment of essential tremor relying on brain connectivity measures derived from MRI.

NCT ID: NCT03832712 Recruiting - Essential Tremor Clinical Trials

The Swedish Essential Tremor (SWEET) Trial

Start date: June 30, 2018
Phase: N/A
Study type: Interventional

To evaluate the effect of deep brain stimulation (DBS) vs best medical treatment in essential tremor (ET) in a randomized, single-blinded controlled trial.

NCT ID: NCT03811405 Not yet recruiting - Parkinson Disease Clinical Trials

Physiology, Imaging and Modeling of Essential Tremor

Start date: June 2019
Phase: N/A
Study type: Interventional

This project aims to investigate novel ways to deliver brain stimulation to Essential Tremor (ET) patients by introducing software changes to their existing devices. The study team aims to investigate safety and efficacy of these new stimulation parameters in patients with ET.

NCT ID: NCT03805750 Recruiting - Essential Tremor Clinical Trials

Trial of Cannabis for Essential Tremor

Start date: January 22, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a pilot trial to evaluate the safety and efficacy of a combined oral formulation of THC and CBD in patients with Essential Tremor.

NCT ID: NCT03795935 Recruiting - Essential Tremor Clinical Trials

Relief From Side Effects: Clinical Use of Electrodes With Direction

Start date: September 17, 2018
Phase: N/A
Study type: Interventional

Deep Brain Stimulation (DBS) uses electrical pulses sent through a lead (insulated wire) to help stop unwanted symptoms in a variety of brain diseases, including the tremor seen in patients with Essential Tremor (ET). The current standard lead allows this stimulation to spread out uniformly in all directions. As these diseases progress, however, the amount of electrical stimulation required to stop the symptom usually increases. This may become problematic because the increased electrical stimulation required for advanced symptoms may spread outside the desired targeted area, and effect other parts of the brain and causing unwanted side effects. A new type of DBS lead has been developed which can steer, or focus, the electrical stimulation in a given direction toward the desired target area and away from areas that would cause side effects. We would like to quantify the benefit seen in patients who have been switched from the traditional lead to this new directional lead.

NCT ID: NCT03794661 Not yet recruiting - Parkinson's Disease Clinical Trials

Evaluation of the Infinity Deep Brain Stimulation Electrode Screening Mode Tool

Start date: February 28, 2019
Phase: N/A
Study type: Interventional

The objective of this clinical investigation is to characterize the clinical performance of Abbott's Clinician Programmer Electrode Screening Mode tool (InformityTM tool) in programming InfinityTM deep brain stimulation (DBS) systems for patients with Parkinson's disease (PD) or essential tremor (ET).

NCT ID: NCT03780426 Recruiting - Essential Tremor Clinical Trials

tSMS in Essential Tremor

Start date: October 1, 2018
Phase: Phase 2
Study type: Interventional

This is randomized double-blind study to study the hypothesis that transcranial static magnetic field stimulation of the primary motor cortex improves tremor in patients with essential tremor. Half of the patients will receive tSMS of the left hemisphere and the other half of the right hemisphere.

NCT ID: NCT03778060 Recruiting - Essential Tremor Clinical Trials

Long-Term Transcutaneous Stimulation and Essential Tremor: A PET Study

Start date: February 11, 2019
Phase: N/A
Study type: Interventional

Essential tremor (ET) is the most common movement disorder in the United States and affects up to 5% of the population. ET patients experience involuntary shaking of the hands, head and/or voice that can range from mildly limiting to severely disabling. Treatment options are limited and there are currently no medications specifically designed to treat it, and medications that are prescribed to relieve tremors are often limited by either inadequate efficacy or intolerable side effects. A subset of essential tremor patients whose tremors are inadequately treated by medication choose to undergo deep brain stimulation (DBS) of the ventral intermediate thalamic nucleus. DBS has been shown to be highly effective for tremor suppression. However, DBS carries significant risks. As a result, a very small (less than 3%) percentage of essential tremor patients undergo DBS therapy. The medical technology company Cala Health has developed a wristband device (the Cala TWO) that offers individuals with essential tremor a novel non-pharmacological, non-invasive alternative, in the form of stimulation of peripheral nerves, to aid in hand tremor relief. This innovative form of therapy has the potential to have important health, quality of life, and economic benefits for essential tremor patients. The present pilot study (Aim 1) will assess the effectiveness of 3-month twice daily treatment with the Cala TWO device to aid in the relief of hand tremors in adult essential tremor subjects that have been approved to undergo deep brain stimulation surgery at Mayo Clinic - Rochester. This study is a prospective, within subject, non-significant risk study at Mayo Clinic - Rochester, enrolling approximately 20 subjects. A completely optional component of this study (Aim 2) is seeking to perform three standard PET/CT sessions on a subset of these subjects (n=10) at Mayo Clinic - Rochester to evaluate changes in brain metabolic activity as a result of 3 months treatment with the device. The first session would take place upon a subjects entry into the study (start of month 1) and prior to any treatment with the Cala device, a second the following day after a 40 minute treatment period with the Cala device, and a third session at the end of the third month. This study is a prospective, within subject, greater than minimum risk study.

NCT ID: NCT03769961 Recruiting - Essential Tremor Clinical Trials

Ataxia in Essential Tremor: Describing the Differences Between Disease Process and Treatment Effect

Start date: December 1, 2018
Study type: Observational

The proposed study aims to characterize ataxia occurring in essential tremor and essential tremor with DBS.